Slate Medicines Appoints Kenneth Koblan as CSO

Company: Slate Medicines · Event Type: Executive Appointment · New CSO: Kenneth Koblan, PhD · Context: SLTE-1009 (PACAP/VIP Antibody) Advancing for Migraine · Date: September 14, 2026 Summary Slate Medicines appointed Kenneth Koblan, PhD, as chief scientific officer while advancing the PACAP/VIP antibody SLTE-1009 for…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs
Aureka Raises $100 Million for AI-Native Drug Discovery
Solstice Oncology Launches with $225 Million Series A
Beeline Therapeutics – $300M Launch